Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Operating Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Operating Expenses for 11 consecutive years, with $130.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses changed N/A to $130.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $138.7 million, a N/A change, with the full-year FY2025 number at $163.5 million, up 308.29% from a year prior.
  • Operating Expenses was $130.8 million for Q4 2025 at Crescent Biopharma, up from $5.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $130.8 million in Q4 2025 to a low of $2.4 million in Q1 2025.
  • A 5-year average of $17.9 million and a median of $11.0 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 63.3% in 2021, then plummeted 78.42% in 2025.
  • Crescent Biopharma's Operating Expenses stood at $17.4 million in 2021, then crashed by 39.1% to $10.6 million in 2022, then decreased by 9.62% to $9.6 million in 2023, then grew by 17.01% to $11.2 million in 2024, then soared by 1064.07% to $130.8 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Operating Expenses are $130.8 million (Q4 2025), $5.5 million (Q3 2025), and $2.4 million (Q1 2025).